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Abstract
Pygopus is a transcriptional activator important for the Wnt signaling pathway. It
binds to the beta-catenin transcriptional complex via the adaptor proteins Bcl9 and Bcl9l
(Bcl9/9l). This complex is considered to be a suitable target for the treatment of tumors
that display activated Wnt signaling. In the mouse, there are two Pygopus-encoding
genes, Pygo1 and Pygo2 (Pygo1/2), with the latter playing a major role. Here we in-
troduce a single amino acid substitution in Pygo2, which was previously shown to ab-
rogate binding to Bcl9/9l, and cause lethality in Drosophila melanogaster. We conﬁrm
that mutant Pygo2 protein fails in interacting with Bcl9 but, unexpectedly, homozygous
mice with this mutation are viable and fertile, even when this mutant allele is combined
with a null mutation of the potentially redundant Pygo1. Based on this observation, we
conjecture that the Pygo-Bcl9/9l interaction requires scant aﬃnity in vivo to fulﬁll de-
velopmental functions and thrust forward the notion that this interaction surface could
be targeted in cancer therapy without major consequences on homeostatic functions.
Objective
Our purpose is to further test the relevance of the Pygo2—Bcl9/9l interaction surface
and the eﬀect of its abrogation on mouse development. This interaction is a candidate
target for the treatment of Wnt signaling-driven tumors.
Introduction
TheWnt signaling pathway drives virtually all aspects of embryonic development, and
its over activation is a causative factor in several human cancers [1]. Beta-catenin is
the molecular fulcrum of canonical Wnt signaling [2]. It binds to several transcriptional
co-factors; among them, Bcl9/9l and Pygo1/2 [3] [4] [5]. Of note, while Pygo1-null mice
are viable and fertile, mice deﬁcient for Pygo2 die between 13.5 days post coitum (dpc)
and birth, presenting a series of developmental defects. Double Pygo1/2 homozygous
mutants do not display any synergy in the severity of the phenotype [6] [7]. Bcl9/9l act
as “bridge” proteins by simultaneously binding beta-catenin (via the HD2 domain) and
Pygo1/2 (via the HD1 domain). The relevance of this protein complex in the mouse is
also supported by previous work: the deletion of the HD1 domain—which fully abro-
gates Bcl9/9l’s ability to bind Pygo1/2—leads to embryonic lethality, recapitulating the
complete loss of Pygo1/2 [8]. Earlier results identiﬁed the amino acids within the Plant
Homology Domain (PHD) of Pygo proteins that are critical for binding to Bcl9/9l: these
mutations (e.g., L789A) lead to embryonic lethality in Drosophila melanogaster [9]. Here
we create the corresponding and functionally analogous mutation in the mouse Pygo2 :
the substitution of the Leucine in position 368 (L368A).
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Figure Legend
Pygo2-L368A-mutant mice have no apparent phenotype.
(A) Schematic overview of the knock-in strategy used to generate the
Pygo2-L368A-mutant allele. Boxes indicate exons, coding sequence is in grey.
Exons and introns are not to scale. The L368 position within the Plant Homology
Domain (PHD) is indicated by a green vertical bar. (B) Left: PCR genotyping of the
Pygo2-L368A mice. Right: sequencing of the mutated allele using, as template, genomic
DNA extracted from homozygous mice. (C) Top: GST-pulldown (GST-PD) experiment
showing that the L368A mutation in the Pygo2 PHD ﬁnger eﬃciently reduces the
Pygo2-Bcl9 binding. Note that a peptide spanning the N-terminal 372 amino acids of
Bcl9 was used. Bottom: Fiji-based band quantiﬁcation of three independent pull- down
experiments-the bands obtained with the pull-down are quantiﬁed over their relative
input, and the band intensity of the WT, for each experiment, is set to 1. The average
value and the standard deviation (StDv) of the three quantiﬁcations are indicated. WT
(W), wild-type; MUT (M), mutant. (D) Pygo2-L368A embryos at 18.5 dpc are normal in
appearance. (E)There are no discernible developmental defects in Pygo2-L368A-mutant
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embryos at 15.5 dpc. From top to bottom: hematoxylin/eosin staining of tissue sections
from developing eye, kidney, and lung.
Results & Discussion
We generated a Pygo2 knock-in mutant allele by introducing a two-nucleotide change
(CT>GC) so that the Leucine in position 368—within the plant homology domain (PHD)
of Pygo2—is replaced by an Alanine (Figure A). The homologous mutation in pygo
(L789A) leads to lethality in Drosophila melanogaster [9]. The mice are genotyped with
primers spanning the remaining FRT sequence that follows the NEO-cassette excision
(Figure B, see Materials and Methods section for a detailed description). The presence
of the mutation is conﬁrmed by DNA sequencing (Figure B). Initially, three indepen-
dent breedings between heterozygous mice (Pygo2L368A/+ X Pygo2L368A/+) gave rise to
mutant homozygous Pygo2L368A/L368A animals (6/44 [13.6%], representing half of the ex-
pected Mendelian ratio). The homozygous mutant mice obtained were then interbred,
giving rise to healthy animals, thereby showing that homozygous Pygo2-L368A mu-
tant mice reach adulthood without any malformation and are fertile. To rule out any
compensatory mechanism due to potential redundancy with Pygo1, we brought the
Pygo2-L368A mutant allele into a Pygo1-knockout background. By crossing Pygo2 het-
erozygous, Pygo1-knockout mice (Pygo1-/-; Pygo2L368A/+), we obtained Pygo1/2 double
mutant animals (Pygo1-/-; Pygo2L368A/L368A) in a proportion of 4/15 (26%—the expected
Mendelian ratio is 1/4). A double mutant male mouse (Pygo1-/-; Pygo2L368A/368A) from
this progeny was successively bred twice with a Pygo1-/-; Pygo2L368A/+ female and gave
rise to a total of 10/23 double mutant mice (43.5%—the expected Mendelian ratio is 1/2).
Both male and female double mutant mice could breed, allowing us to establish a colony
of healthy Pygo1-/-; Pygo2L368A/L368A animals.
The eﬀect of the L368A mutation on the Pygo2—Bcl9 interaction was conﬁrmed by
in vitro GST pull-down experiments. We extracted proteins from adult wild-type and
mutant kidneys, an abundant source for Pygo2 protein [10]. We incubated wild-type
and mutant protein extracts with a recombinant GST-Bcl9 protein fragment (amino
acids 1—372 of mouse Bcl9, that includes the region spanning two relevant domains:
HD1 [Pygo-binding] and HD2 [beta-catenin-binding]). GST-GFP was used as nega-
tive control. With glutathione-conjugated sepharose beads, we pulled down the GST-
proteins and performed Western blot analysis to detect Pygo2 in the pull-down reac-
tions. Whereas the GST-Bcl9 can strongly interact with the wild-type Pygo2, it fails
in signiﬁcantly pulling down the Pygo2-L368A mutated protein (Figure C, compare the
bands indicated by the two white asterisks).
Pygo1/2 double knockout mice die during embryonic development between 13.5 dpc and
birth due to a series of developmental defects [11] [8]. However, Pygo2-L368A embryos
are, in their superﬁcial appearance, indistinguishable from wild-type littermates (Fig-
ure D). Out of 25 embryos analyzed, we scored six mutants (24%, close to the expected
Mendelian ratio of 1/4). Moreover, histological analyses of the tissues aﬀected during
development in Pygo1/2-knockout mice (mainly the lens, the lungs, and the kidney [11]
[6]) reveal no obvious alterations at 15.5 dpc (Figure E).
The complete abrogation of the interaction between Bcl9/9l and Pygo1/2—via the dele-
tion of the HD1 domain in both Bcl9 and Bcl9l—leads to embryonic lethality at 13.5 dpc,
with a striking “Pygo knockout” phenotype [8]. These results appear contradictory (see
also the Alternative Explanations paragraph). It is possible that the deletion of the full
Pygo-interacting HD1 domain of Bcl9/9l completely abrogates their interaction, while
the single amino acid substitution L368A in Pygo2 strongly reduces their binding, but
leaves some residual interaction. Thus, the residual binding between Pygo2-L368A and
Bcl9 would be capable of fulﬁlling all the developmental functions for which this inter-
action is required. It is possible, in fact, that this interaction is weak and dynamic in
nature in vivo. The extent to which the mutation L368A decreases the aﬃnity between
Pygo2 and Bcl9 remains to be determined. In conclusion, we cannot observe any de-
velopmental or homeostatic defect in mutant Pygo1-/-; Pygo2L368A/L368A mice: they reach
adulthood healthy and fertile. Because several reports have previously shown that the
interaction between Pygo1/2 and Bcl9/9l is necessary for proper development [9] [12]
[8], we propose that only a weak interaction between these factors is required.
Pygo2-L368A mice are viable and fertile despite displaying strongly reduced
Pygo2-Bcl9/9l binding.
The main limitation of this study consists in the fact that, by using an in vitro binding
assay to demonstrate the decreased aﬃnity between the mutant Pygo2 and Bcl9, we
cannot exclude that this interaction is intact in the cell.
Pygo2 overexpression has been shown to drive elevated Wnt signaling as potential
causative factor in diﬀerent types of tumors [12] [13] [14] [15]. It will be necessary
to test whether the decreased aﬃnity between Pygo2-L368A and Bcl9/9l is mirrored by
an attenuated Wnt signaling. We conjecture that this mouse model could serve as an
ideal tool to test, as proof of principle, if the Bcl9/9l-interacting surface of Pygo pro-
teins could constitute the target of small compounds/inhibitors aimed at dampening the
aberrantly activated Wnt signaling in these tumors.
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